Early Data Show Antibody Cocktail Prevents Symptomatic COVID-19 Infection
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
The combination therapy reduced the risk of hospitalization or death by 70%.
Chemet is an orally active, heavy metal chelating agent indicated for the treatment of lead poisoning in pediatric patients.
While both candidates were found to be generally well tolerated, findings showed immune responses that were inferior to those seen after natural infection or those reported with other COVID-19 vaccines.
Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor.
Zokinvy works by preventing farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.
The approval was based on data from an open-label, single-arm study that evaluated the efficacy and safety of Nerivio in patients aged 12 to 17 years with migraine.
In the US, a phase 1 study will evaluate mRNA-1273.351, an emerging variant booster candidate against the B.1.351 variant.
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
To identify medications with potential proarrhythmic association.